Hepion Pharmaceuticals, Inc.

Equities

HEPA

US4268973025

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-25 pm EDT			5-day change	1st Jan Change
1.29 ^USD	-2.27%		-38.91%	-60.19%

Apr. 22	Sector Update: Health Care Stocks Increase Late Afternoon	MT
Apr. 22	Sector Update: Health Care	MT

Hepion Pharmaceuticals, Inc Announces Demise of Thomas Adams, Ph.D., Member of Its Board of Directors

January 12, 2022 at 08:00 am EST

Hepion Pharmaceuticals, Inc. announced the passing of Thomas Adams, Ph.D., a member of its Board of Directors. Dr. Adams died of natural causes on January 9, 2022. A seasoned biotechnology veteran, Dr. Adams was appointed to Hepion's Board in September 2016.

Latest news about Hepion Pharmaceuticals, Inc.

Sector Update: Health Care Stocks Increase Late Afternoon	Apr. 22	MT
Sector Update: Health Care	Apr. 22	MT
Top Midday Decliners	Apr. 22	MT
North American Morning Briefing: Stock Futures Rise, Busy Week of Earnings Ahead	Apr. 22	DJ
Hepion Pharmaceuticals Starts Wind-Down Activities in Phase 2b ASCEND-NASH Trial	Apr. 19	MT
Hepion Pharmaceuticals, Inc. Initiates Wind-Down Activities in Phase 2b ?ASCEND-NASH? Trial	Apr. 19	CI
Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 16	CI
Hepion Pharmaceuticals, Inc. Appoints Michael Purcell to Its Board of Directors	Mar. 06	CI
Hepion Pharmaceuticals, Inc. Announces Board Changes	Feb. 20	CI
Hepion Pharmaceuticals, Inc. Announces Resignation of Anand Reddi from the Board of Directors	Feb. 07	CI
North American Morning Briefing : Futures Pause -2-	Dec. 08	DJ
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value	Dec. 07	CI
Hepion Pharmaceuticals Approves Restructuring Plan to Preserve Capital, Launches Strategic Review Process	Dec. 07	MT
Hepion Pharmaceuticals, Inc. Announces Resignation of Robert Foster as Director	Dec. 07	CI
Hepion Pharmaceuticals, Inc. Announces CEO Changes	Dec. 07	CI
Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 20	CI
Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-Week Phase 2 Study of Advanced (F3) Mash Liver Disease	Nov. 13	CI
Hepion Pharmaceuticals, Inc. Announces the Publication of New Research Study in Mice	23-10-25	CI
Hepion Pharmaceuticals, Inc. announced that it has received $5.000004 million in funding	23-10-02	CI
Hepion Pharmaceuticals, Inc. announced that it expects to receive $5.000004 million in funding	23-09-27	CI
Hepion Pharmaceuticals, Inc. Announces Results from A Study with in Which the Anti-Cancer Activity of Hepion's Lead Drug Candidate, Rencofilstat	23-09-21	CI
Aurinia Pharmaceuticals Appoints Robert Foster as Part of Deal With Shareholder MKT Capital	23-09-21	MT
Hepion Pharmaceuticals Reports Novel Rencofilstat Action in Liver Cancer	23-09-19	MT
Hepion Says Research Study on Idiopathic Pulmonary Fibrosis Involving Drug Candidate Rencofilstat Showed Positive Results	23-09-14	MT
Hepion Pharmaceuticals, Inc. Announces Positive Results from Translational Research Study	23-09-14	CI

Chart Hepion Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Hepion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of drug therapy for treatment of chronic liver diseases. This therapeutic approach targets fibrosis, inflammation, and the treatment hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH), viral hepatitis and other liver diseases. The Company's cyclophilin inhibitor, rencofilstat is developed to offer benefits to address multiple complex pathologies relate to advanced liver disease. The Companyâs rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease. The Company provides an artificial intelligence (AI) tool, AI-POWR, that allows the selection of novel drug targets, biomarkers, and appropriate patient populations. The components of AI-POWR include access to publicly available databases, and in-house genomic and multi-omic big.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.29 USD

Average target price

30 USD

Spread / Average Target

+2,225.58%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
HEPION PHARMACEUTICALS, INC.	-60.19%	7.22M
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	104B
REGENERON PHARMACEUTICALS, INC.	+1.41%	97.42B
ARGENX SE	+0.79%	22.2B
BIONTECH SE	-17.84%	21.23B
GENMAB A/S	-11.11%	18.33B
WUXI APPTEC CO., LTD.	-42.83%	16.35B
BEIGENE, LTD.	-17.63%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.98B
SAREPTA THERAPEUTICS, INC.	+32.11%	11.66B

Bio Therapeutic Drugs